Your browser doesn't support javascript.
loading
Engineered Protein Copolymers for Heparin Neutralization and Detection.
Liu, Qing; Shaukat, Ahmed; Meng, Zhuojun; Nummelin, Sami; Tammelin, Tekla; Kontturi, Eero; de Vries, Renko; Kostiainen, Mauri A.
  • Liu Q; Biohybrid Materials, Department of Bioproducts and Biosystems, Aalto University, Aalto00076, Finland.
  • Shaukat A; Wenzhou Institute, University of Chinese Academy of Sciences (WIUCAS), Wenzhou325001, China.
  • Meng Z; Biohybrid Materials, Department of Bioproducts and Biosystems, Aalto University, Aalto00076, Finland.
  • Nummelin S; Wenzhou Institute, University of Chinese Academy of Sciences (WIUCAS), Wenzhou325001, China.
  • Tammelin T; Materials Chemistry of Cellulose, Department of Bioproducts and Biosystems, Aalto University, Aalto00076, Finland.
  • Kontturi E; Biohybrid Materials, Department of Bioproducts and Biosystems, Aalto University, Aalto00076, Finland.
  • de Vries R; VTT Technical Research Centre of Finland Ltd, VTT, P.O. Box 1000, EspooFI-02044, Finland.
  • Kostiainen MA; Materials Chemistry of Cellulose, Department of Bioproducts and Biosystems, Aalto University, Aalto00076, Finland.
Biomacromolecules ; 24(2): 1014-1021, 2023 02 13.
Article en En | MEDLINE | ID: mdl-36598935
ABSTRACT
Heparin is a widely applied anticoagulant agent. However, in clinical practice, it is of vital importance to reverse its anticoagulant effect to restore the blood-clotting cascade and circumvent side effects. Inspired by protein cages that can encapsulate and protect their cargo from surroundings, we utilize three designed protein copolymers to sequester heparin into inert nanoparticles. In our design, a silk-like sequence provides cooperativity between proteins, generating a multivalency effect that enhances the heparin-binding ability. Protein copolymers complex heparin into well-defined nanoparticles with diameters below 200 nm. We also develop a competitive fluorescent switch-on assay for heparin detection, with a detection limit of 0.01 IU mL-1 in plasma that is significantly below the therapeutic range (0.2-8 IU mL-1). Moreover, moderate cytocompatibility is demonstrated by in vitro cell studies. Therefore, such engineered protein copolymers present a promising alternative for neutralizing and sensing heparin, but further optimization is required for in vivo applications.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Heparina / Anticoagulantes Tipo de estudio: Diagnostic_studies Idioma: En Año: 2023 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Heparina / Anticoagulantes Tipo de estudio: Diagnostic_studies Idioma: En Año: 2023 Tipo del documento: Article